Palo Alto Investors’s Clovis Oncology, Inc. CLVS Stock Holding History

Palo Alto Investors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,473,967	Closed	-$5.32M	–	33
2022 Q3	$5.32M	Hold	4,473,967	–	–	0.42%	23
2022 Q2	$8.05M	Hold	4,473,967	–	–	0.7%	21
2022 Q1	$9.04M	Buy	4,473,967 +476,141	+12%	+$935K	0.7%	22
2021 Q4	$10.8M	Sell	3,997,826 -486,585	-11%	-$1.8M	0.69%	23
2021 Q3	$20M	Hold	4,484,411	–	–	1.21%	19
2021 Q2	$26M	Hold	4,484,411	–	–	1.43%	17
2021 Q1	$31.5M	Buy	4,484,411 +15,000	+0.3%	+$101K	1.79%	17
2020 Q4	$21.5M	Hold	4,469,411	–	–	1.12%	17
2020 Q3	$26.1M	Buy	4,469,411 +108,000	+2%	+$646K	1.43%	16
2020 Q2	$29.4M	Sell	4,361,411 -274,378	-6%	-$2.08M	1.77%	16
2020 Q1	$29.5M	Sell	4,635,789 -420,497	-8%	-$3.37M	2.47%	15
2019 Q4	$52.7M	Buy	5,056,286 +335,542	+7%	+$2.44M	2.9%	15
2019 Q3	$18.6M	Sell	4,720,744 -420,560	-8%	-$3.4M	1.24%	20
2019 Q2	$76.5M	Sell	5,141,304 -98,000	-2%	-$1.77M	3.72%	13
2019 Q1	$130M	Hold	5,239,304	–	–	5.43%	8
2018 Q4	$94.1M	Buy	5,239,304 +18,278	+0.4%	+$373K	5.01%	8
2018 Q3	$153M	Buy	5,221,026 +247,019	+5%	+$9.56M	6.2%	6
2018 Q2	$226M	Buy	4,974,007 +1,018,347	+26%	+$49.5M	9.04%	3
2018 Q1	$209M	Buy	3,955,660 +552,879	+16%	+$32.3M	8.93%	2
2017 Q4	$231M	Buy	3,402,781 +73,200	+2%	+$5.12M	9.97%	3
2017 Q3	$274M	Hold	3,329,581	–	–	11.56%	2
2017 Q2	$312M	Sell	3,329,581 -565,382	-15%	-$34.6M	14.55%	1
2017 Q1	$248M	Buy	3,894,963 +90,875	+2%	+$5.52M	11.72%	2
2016 Q4	$169M	Hold	3,804,088	–	–	9.64%	3
2016 Q3	$137M	Hold	3,804,088	–	–	7.97%	4
2016 Q2	$52.2M	Buy	3,804,088 +342,723	+10%	+$5.01M	3.94%	5
2016 Q1	$66.5M	Sell	3,461,365 -86,354	-2%	-$1.83M	5.16%	6
2015 Q4	$124M	Buy	3,547,719 +438,911	+14%	+$28.3M	6.91%	5
2015 Q3	$286M	Buy	3,108,808 +707,691	+29%	+$61.2M	13.75%	2
2015 Q2	$211M	Buy	2,401,117 +279,260	+13%	+$23.9M	9.38%	4
2015 Q1	$158M	Buy	2,121,857 +19,000	+0.9%	+$1.34M	7.79%	5
2014 Q4	$118M	Buy	2,102,857 +381,100	+22%	+$20M	6.91%	4
2014 Q3	$78.1M	Buy	1,721,757 +806,436	+88%	+$33.7M	5.83%	6
2014 Q2	$37.9M	Buy	915,321 +728,421	+390%	+$37.5M	2.82%	11
2014 Q1	$12.9M	Hold	186,900	–	–	1.07%	22
2013 Q4	$11.3M	Buy	+186,900	New	+$10.2M	1.05%	23

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Palo Alto Investors's CLVS Position: Q4 2022 in Review

Palo Alto Investors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 4,473,967 shares — an estimated $5.32M sold.

Palo Alto Investors first reported a position in CLVS in Q4 2013 and held it in 36 quarters. The position peaked at $312M in Q2 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Palo Alto Investors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Palo Alto Investors sold 4,473,967 Clovis Oncology, Inc. shares in Q4 2022, an estimated $5.32M.
Palo Alto Investors first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 36 quarters.
Palo Alto Investors's Clovis Oncology, Inc. position peaked at $312M in Q2 2017.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Palo Alto Investors's 13F filing for Q4 2022, filed 14 Feb 2023.